These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28292481)

  • 1. Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T; Moriwaki K
    Value Health; 2017 Mar; 20(3):372-378. PubMed ID: 28292481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Application of Cost-Effectiveness Evaluation in the Japanese National Health Insurance System.
    Ogura H; Komoto S; Shiroiwa T; Fukuda T
    Int J Technol Assess Health Care; 2019; 35(6):452-460. PubMed ID: 30894242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment in Japan: a work in progress.
    Kamae I; Thwaites R; Hamada A; Fernandez JL
    J Med Econ; 2020 Apr; 23(4):317-322. PubMed ID: 31944134
    [No Abstract]   [Full Text] [Related]  

  • 11. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reconsideration of the admission and discharge criteria of tuberculosis patients in Japan].
    Masuyama H; Igari H
    Kekkaku; 2013 Mar; 88(3):373-85. PubMed ID: 23672177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are guidelines for measurement of quality of life contrary to patient-centred care?
    Disher T; Beaubien L; Campbell-Yeo M
    J Adv Nurs; 2018 Nov; 74(11):2677-2684. PubMed ID: 30109711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan.
    Shiroiwa T
    Int J Technol Assess Health Care; 2020 Jun; 36(3):270-276. PubMed ID: 32419677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
    Cromwell J; Bartosch WJ; Fiore MC; Hasselblad V; Baker T
    JAMA; 1997 Dec; 278(21):1759-66. PubMed ID: 9388153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices-A European Perspective.
    Messori A; Trippoli S
    Ther Innov Regul Sci; 2018 Nov; 52(6):755-756. PubMed ID: 29714590
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective.
    Ademi Z; Gloy V; Glinz D; Raatz H; Van Stiphout J; Bucher HC; Schwenkglenks M
    Swiss Med Wkly; 2016; 146():w14382. PubMed ID: 27922167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based clinical guidelines in Kyrgyz Republic.
    Zurdinova AA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S45-6. PubMed ID: 26639705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.